3E03002 ICD-10-PCS Code: Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach
Introduce of High dose IL-2 into Periph Vein, Open Approach
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | Section3 | Administration |
| 2 | Body SystemE | Physiological Systems and Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body System / Region3 | Peripheral Vein |
| 5 | Approach0 | Open |
| 6 | Substance0 | Antineoplastic |
| 7 | Qualifier2 | High-dose Interleukin-2 |
MS-DRG Grouper Relationships (FY2026)
Potential MS-DRG participation — not a DRG assignment.
The MS-DRG grouper treats this as a non-operating-room procedure. It appears in the surgical logic of 2 MS-DRGs:
From the CMS MS-DRG Definitions Manual, Appendix E. Actual DRG assignment depends on the complete claim.
Related Codes
Same operation — other Body System / Region
Same table and root operation, differing only in the body system / region character.
3E04002 — Introduction of High-dose Interleukin-2 into Central Vein, Open Approach, 3E05002 — Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach, 3E06002 — Introduction of High-dose Interleukin-2 into Central Artery, Open Approach
Same operation — other Approach
Same table and root operation, differing only in the approach character.
3E03302 — Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach
Same operation — other Qualifier
Same table and root operation, differing only in the qualifier character.
3E03003 — Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach, 3E03005 — Introduction of Other Antineoplastic into Peripheral Vein, Open Approach, 3E0300M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach, 3E0300P — Introduction of Clofarabine into Peripheral Vein, Open Approach
Same procedure category (CCSR), other tables
AHRQ's Clinical Classifications Software Refined groups these ICD-10-PCS procedures with this one under Chemotherapy (Administration of Therapeutic Substances); listed here are the members in other PCS tables. Source: Clinical Classifications Software Refined (CCSR), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality, November 2025.
XW01318 — Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8, XW01329 — Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW01348 — Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8, XW013L9 — Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW013S9 — Introduction of Epcoritamab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9, XW03358 — Introduction of Mosunetuzumab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03368 — Introduction of Afamitresgene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03378 — Introduction of Tabelecleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW03387 — Introduction of Lurbinectedin into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW03388 — Introduction of Treosulfan into Peripheral Vein, Percutaneous Approach, New Technology Group 8, XW0338A — Introduction of Obecabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW0339A — Introduction of Odronextamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033A7 — Introduction of Ciltacabtagene Autoleucel into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033B3 — Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3, XW033B7 — Introduction of Amivantamab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033BA — Introduction of Orca-T Allogeneic T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033C7 — Introduction of Autologous Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033CA — Introduction of Zanidatamab Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 10, XW033G7 — Introduction of Allogeneic Engineered Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, XW033H7 — Introduction of Axicabtagene Ciloleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 7, +40 more
Contextual Map
Every relationship of 3E03002 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
Run 3E03002 with these 5 related codes in Claim Check
PCS table
- 3E0[PCS table]— CMS ICD-10-PCS tables
- Administration — Section: Administration[Section]: “Administration”— CMS ICD-10-PCS tables
- Physiological Systems and Anatomical Regions — Body System: Physiological Systems and Anatomical Regions[Body System]: “Physiological Systems and Anatomical Regions”— CMS ICD-10-PCS tables
- Introduction — Operation: Introduction[Operation]: “Introduction”— CMS ICD-10-PCS tables
MS-DRG participation
- DRG 837 — CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC[MS-DRG]: “CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC — Chemotherapy with Acute Leukemia As Secondary Diagnosis (MDC 17)”— CMS MS-DRG Definitions Manual (Appendix E) · FY2026
- DRG 838 — CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT[MS-DRG]: “CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT — Chemotherapy with Acute Leukemia As Secondary Diagnosis (MDC 17)”— CMS MS-DRG Definitions Manual (Appendix E) · FY2026
Clinical classification (CCSR)
- ADM012 — Chemotherapy[CCSR category]: “Chemotherapy — Administration of Therapeutic Substances”— AHRQ CCSR for ICD-10-PCS Procedures (HCUP) · v2026.1
MDC crossing · diagnoses (665)
- MDC 17 — Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms[MDC crossing]: “Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms — the grouper's crossing between diagnoses and procedures: a principal diagnosis sets the MDC, and same-MDC procedures move the stay to its surgical DRGs.”— CMS MS-DRG Definitions Manual · FY2026
- C26.1 — Malignant neoplasm of spleen[Same-MDC diagnosis]: “Malignant neoplasm of spleen — grouped in MDC 17, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2026
- C37 — Malignant neoplasm of thymus[Same-MDC diagnosis]: “Malignant neoplasm of thymus — grouped in MDC 17, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2026
- C45.7 — Mesothelioma of other sites[Same-MDC diagnosis]: “Mesothelioma of other sites — grouped in MDC 17, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2026
- C45.9 — Mesothelioma, unspecified[Same-MDC diagnosis]: “Mesothelioma, unspecified — grouped in MDC 17, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2026
- C46.3 — Kaposi's sarcoma of lymph nodes[Same-MDC diagnosis]: “Kaposi's sarcoma of lymph nodes — grouped in MDC 17, the diagnosis side of this code's crossing.”— CMS MS-DRG Definitions Manual (Appendix B) · FY2026
- and 660 more
Nearest codes
- 3E03003 — Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E03005 — Introduction of Other Antineoplastic into Peripheral Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E0300M — Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E0300P — Introduction of Clofarabine into Peripheral Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E03302 — Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach[One axis away]— CMS ICD-10-PCS tables
- 3E04002 — Introduction of High-dose Interleukin-2 into Central Vein, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E05002 — Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach[One axis away]— CMS ICD-10-PCS tables
- 3E06002 — Introduction of High-dose Interleukin-2 into Central Artery, Open Approach[One axis away]— CMS ICD-10-PCS tables
Change history
No changes recorded for this code. This ledger tracks additions, deletions and description changes from FY2026 (April) onward. Note changes are not tracked.
Read from: CMS ICD-10-PCS code tables, index and definitions — FY2026 (April); CMS MS-DRG Definitions Manual (incl. Appendix B diagnosis index, Appendix C CC/MCC list, Appendix E procedure index) and IPPS Final Rule tables — v43; AHRQ HCUP Clinical Classifications Software Refined for ICD-10-PCS Procedures (hcup-us.ahrq.gov/toolssoftware/ccsr/PRCCSR_v2026-1.zip) — v2026.1. All data sources · How to read the labels